Category: Company news

Drug monitoring – Immunosuppressant Latest Update

The NanoDem project is reaching its conclusion with the successful development of a prototype analyser.  Partners met in Munich Nov 28 to Dec 1st for the final review meeting which involved assessment by the EC project officer.  Clinical evaluations will take place during the summer 2017 on receiving ethics committee approval which is expected any…
Read more »

Nanodem – Immunosuppressant monitoring

Mark O’Connell will be presenting at the forthcoming NANODEM meeting 28th Nov to Dec 1st. A proposal for ethics approval has been submitted and clinical work is planned to commence in the new year. Probe’s MicroEye forms the basis of the patient interface for the therapeutic drug monitoring project which is studying immunosuppressant levels continuously…
Read more »

ICS State of the Art 2016 (5-7 December ExCel London)

Probe will be exhibiting at the ICS State of the Art meeting in December. We will be showing our systems for continuous glucose and lactate monitoring We will be discussing the importance and practicality of automated monitoring, delivering better data without the need for constant attention. We will also be interested to hear from anyone…
Read more »

Sepsis Unplugged

The UK Sepsis Trust ‘Sepsis Unplugged’ Conference 2016 Hosted by The UK Sepsis Trust, this conference will bring together all healthcare professions and patient groups as equals and will ask the questions which will help shape better care for patients with sepsis. Probe will be exhibiting at “ Sepsis Unplugged” in Brighton from the 13th…
Read more »

SUCCESSFUL volunteer studies

Probe has recently conducted a number of successful volunteer studies at it Bedford laboratories. These studies will continue throughout the autumn during which time Probe will be recruiting additional clinical partners for the next stage of studies.